skip to main content

Gout flare prophylaxis during urate-lowering therapy in haemodialysis — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateColchicineGout flare prophylaxis during urate-lowering therapy in haemodialysisSCE Rheumatology

A 66-year-old man with crystal-proven tophaceous gout has had four flares in the past year. He has recently commenced thrice-weekly haemodialysis for end-stage kidney disease. His serum urate is 586 micromol/L, and a rheumatology–renal multidisciplinary plan has been made to initiate and titrate allopurinol. He has no current flare. When his eGFR was 35 mL/min/1.73 m², he tolerated reduced-dose colchicine prophylaxis. He also has a history of a perforated peptic ulcer while taking naproxen despite proton-pump inhibitor therapy, so further NSAID treatment is considered unsuitable. There is no active infection or other major contraindication to a short course of low-dose glucocorticoid therapy. After discussion of benefits and risks, he wishes to receive pharmacological flare prophylaxis during urate-lowering therapy titration. Which is the most appropriate prophylaxis plan?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Use a low-dose oral corticosteroid while the serum urate target is being reached

Explanation lettering: E = shown as C · C = shown as E

NICE recommends offering colchicine to people who choose pharmacological flare prophylaxis while urate-lowering therapy is being initiated or titrated. If colchicine is contraindicated, not tolerated or ineffective, a low-dose NSAID or low-dose oral corticosteroid should be considered. This patient is receiving haemodialysis, and the current UK colchicine SmPC states that colchicine should not be used in haemodialysis because it is not removed by dialysis. His previous tolerance at a higher eGFR does not make post-dialysis dosing safe. His previous perforated ulcer despite gastroprotection makes an NSAID the less appropriate NICE-listed alternative; therefore low-dose oral corticosteroid prophylaxis is the best answer. A is attractive because reduced-frequency colchicine is used in lesser degrees of renal impairment, but haemodialysis is a specific contraindication rather than an indication for dose timing. C is a recognised alternative when colchicine cannot be used, but his complicated ulcer occurred despite proton-pump inhibitor therapy. D is reserved for situations in which colchicine, NSAIDs and corticosteroids are all contraindicated, ineffective or not tolerated, with rheumatology involvement. E could follow an informed decision to decline prophylaxis, but he has chosen it and has frequent, tophaceous disease with a high anticipated mobilisation-flare risk.

Reference: Gout: diagnosis and management — Recommendations (June 2022) — https://www.nice.org.uk/guidance/ng219/chapter/Recommendations Colchicine 500 microgram Tablets — Summary of Product Characteristics (26 February 2026) — https://www.medicines.org.uk/emc/product/14362/smpc